Stocks Health care EVO

NASDAQ · Health care

Evotec SE (EVO)

Evotec SE reported revenue of €797M in fiscal 2024, up 2.0% from a year earlier. It posted a net loss of €196.1M. In fiscal 2024 capital spending exceeded operating cash flow by €99.2M. At December 31, 2024 it held €306.4M in cash against €287.6M of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on April 8, 2026.

Watch EVO in 60 seconds

What Evotec SE does

Evotec SE is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker EVO.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in EUR.

Key figures

Full financial statements: income, balance sheet and cash flow

Where EVO ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Evotec SE has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 9, 2026
   Foreign issuer update 6-K
2. August 13, 2026
   Foreign issuer update 6-K
3. July 14, 2026
   Foreign issuer update 6-K
4. June 30, 2026
   Foreign issuer update 6-K
5. June 17, 2026
   Foreign issuer update 6-K
6. May 6, 2026
   Foreign issuer update 6-K
7. May 1, 2026
   Activist stake changed SCHEDULE 13D/A
8. April 30, 2026
   Foreign issuer update 6-K
9. April 24, 2026
   Foreign issuer update 6-K
10. April 8, 2026
    Foreign issuer update 6-K

Insider trades

What the people running Evotec SE did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns EVO

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Novo Holdings A/S 0% (February 17, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about EVO

What does Evotec SE do?

Evotec SE is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker EVO.

Is Evotec SE profitable?

No. In fiscal 2024 it reported a net loss of €196.1M on revenue of €797M.

How much revenue does Evotec SE make?

In fiscal 2024 Evotec SE reported revenue of €797M. That is 2.0% more than a year earlier.

When did Evotec SE last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on April 8, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 9, 2026.

Similar companies

Compare EVO with

Compare EVO with any company

Follow EVO

Get an email when Evotec SE files with the SEC: results, executive changes, material agreements and annual reports.

Follow EVO: get an email when it files

Where the numbers come from

Financial figures are the values Evotec SE tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.